Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Journal: Rheumatology (Oxford, England)
Published: January 11, 2017
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 14, 2016
Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.
Journal: Advances in therapy
Published: March 22, 2016
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis.
Journal: Rheumatology and therapy
Published: March 15, 2016
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Journal: Annals of the rheumatic diseases
Published: January 17, 2016
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: January 06, 2016
A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Journal: Postgraduate medicine
Published: November 19, 2015
Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Journal: Drug design, development and therapy
Published: July 15, 2015
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
Journal: Annals of the rheumatic diseases
Published: May 13, 2015
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Journal: Seminars in arthritis and rheumatism
Published: December 16, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026